ArticleNeuro-oncology advances

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.

Huanwen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.